Buying the Treasury for Free: A Quick Take on Lakefront Biotherapeutics

Cash-First, Questions Later

This will be a “best ideas only” bio substack providing actionable, highly digestible and high conviction value to investors focused on quality not quantity. Disclaimer: Nothing in this article (or substack) is considered investment advice and is solely the opinion of the author.

There is a version of the Lakefront Biotherapeutics (LKFT) story that sounds like a punchline. A Belgian biotech that spent twenty-seven years failing to get a drug approved, blew its biggest bet on a cell therapy business it then had to quietly shutter after no buyer showed up, cycled through CEOs, and then decided the right move was to rename itself after a geographical feature and start over. That version is not wrong. It is just incomplete, and the part it leaves out is the only part that matters to an investor looking at the stock today.

Lakefront is sitting on approximately €2 billion in cash and financial investments at year-end 2026. The market cap is $1.88 billion. You do not need a spreadsheet to see the problem with that arithmetic, or rather the opportunity in it. The market is currently pricing Lakefront at a meaningful discount to its own treasury, which means you are being handed the pipeline, the Gilead relationship, the new management team, and the buyback authorization for less than nothing. That is the setup in its simplest form, and it is the kind of setup that tends to attract the sort of attention that eventually closes the gap.